Home > Resources > Whitepapers > Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?

Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?

February 12, 2019

The incidences of pharmacy fraud involving pharmaceutical manufacturers’ co-pay card programs are on the rise. In this white paper, TrialCard discusses the steps it has taken to expand its Pharmacy Fraud Monitoring service, which identifies fraud and greatly reduces the reimbursement funds that make it back to the pharmacies in question. This approach has delivered proven results to TrialCard’s pharmaceutical clients and has saved brands valuable reimbursement dollars that otherwise would have been lost.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Tecnimede Group - Pharmaceutical Company

TECNIMEDE GROUP is composed by pharmaceutical companies of private and 100% Portuguese capital. Started its activity in 1980 and covers the entire life cycle of the medicinal products for human use: development, manufacture, promotion and marketing. TECNIMEDE GROUP's strategy is based on a strong investment in Research, Development and Production of Medicinal Products.

OTHER WHITEPAPERS
news image

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More
news image

A Futuristic Approach to Message Testing for Pharma Companies

whitePaper | March 10, 2023

In the last decade, the pharma industry has gone through significant changes in how it messages to physicians, patients and payers. The processes and tools that pharma brands use to DEVELOP and DELIVER messages have been disrupted by new technologies.

Read More
news image

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More

A Futuristic Approach to Message Testing for Pharma Companies

whitePaper | March 10, 2023

In the last decade, the pharma industry has gone through significant changes in how it messages to physicians, patients and payers. The processes and tools that pharma brands use to DEVELOP and DELIVER messages have been disrupted by new technologies.

Read More

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Read More

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of
the factors that impact materials selection can be
daunting for biopharmaceutical companies embarking on a new drug development project. 

Read More
More Whitepapers

Spotlight

Tecnimede Group - Pharmaceutical Company

TECNIMEDE GROUP is composed by pharmaceutical companies of private and 100% Portuguese capital. Started its activity in 1980 and covers the entire life cycle of the medicinal products for human use: development, manufacture, promotion and marketing. TECNIMEDE GROUP's strategy is based on a strong investment in Research, Development and Production of Medicinal Products.

Events